Published Technical Disclosure Archive

Enhanced Implantable Cellular and Biotherapeutic Agent Delivery Canister

Publication ID: 24-11857673_0001_PTD
Published: October 28, 2025
Category:Direct Improvements & Enhancements

Legal Citation

pr1or.art Inc., “Enhanced Implantable Cellular and Biotherapeutic Agent Delivery Canister,” Published Technical Disclosure No. 24-11857673_0001_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857673_0001_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,673.

Summary of the Inventive Concept

An implantable device for delivering cellular and biotherapeutic agents with improved nanophase tubular structure, enhancing agent release and diffusion exchange.

Background and Problem Solved

The original patent's implantable cellular and biotherapeutic agent delivery canister has limitations in terms of agent release and diffusion exchange. The new inventive concept addresses these limitations by incorporating a porous metal canister with a controlled nanophase tubular structure, enhancing metabolically active agent release and facilitating fluid and diffusion exchange.

Detailed Description of the Inventive Concept

The new inventive concept comprises a system for delivering cellular and biotherapeutic agents, featuring a porous metal canister with a nanophase tubular structure having a controlled thickness of 50-100 microns. This structure is integrated with a substrate to facilitate fluid and diffusion exchange to the agents. The canister is designed with a bicontinuous morphology to enhance metabolically active agent release. Additionally, the device includes a rigid, through-porous membrane integrated with a metallic capsule, and a nanophase tubular structure having a diameter of 50-500 nm to facilitate agent release. The system enables a controlled and efficient release of agents, improving treatment outcomes.

Novelty and Inventive Step

The new inventive concept introduces a controlled nanophase tubular structure with a specific thickness range, a bicontinuous morphology, and a rigid, through-porous membrane, which are not present in the original patent. These features provide an enhanced and more efficient delivery of cellular and biotherapeutic agents.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include varying the nanophase tubular structure's thickness, diameter, and material composition to optimize agent release and diffusion exchange. Additionally, the device could be adapted for use in different disease conditions or with various types of agents.

Potential Commercial Applications and Market

The enhanced implantable cellular and biotherapeutic agent delivery canister has significant commercial potential in the pharmaceutical and biotechnology industries, particularly in the treatment of chronic and costly disease conditions. The device could be marketed as a more efficient and effective alternative to traditional pharmaceutical-based therapies.

CPC Classifications

SectionClassGroup
A A61 A61K9/0024
A A61 A61F2/022
A A61 A61K31/337
A A61 A61K31/397
A A61 A61K31/436
A A61 A61K31/65
A A61 A61K31/7036
A A61 A61K35/28
A A61 A61K38/14
A A61 A61K38/1866
A A61 A61K38/22
A A61 A61K39/395
A A61 A61K47/02
A A61 A61M39/0247
A A61 A61M2039/027
A A61 A61M2039/0261
A A61 A61M2039/0276
A A61 A61M2205/04

Field of Art

Biomedical engineering focused on implantable drug delivery systems, specifically nanoporous materials for cellular and biotherapeutic agent encapsulation and controlled release, requiring expertise in materials science, nanotechnology, and medical device design

Person of Ordinary Skill (PHOSITA) Profile

A biomedical engineer or materials scientist with advanced degree, working knowledge of nanofabrication techniques, understanding of medical device design principles, and experience with implantable drug delivery technologies

Obviousness Rationale

A PHOSITA would recognize that the PTD's variations represent predictable engineering modifications to the source patent's core nanoporous implantable device concept. The disclosed changes in nanophase tubular structure thickness, diameter, and morphology are routine optimization strategies within the established technological framework. These modifications would be considered straightforward design choices that a skilled practitioner could readily conceive using standard materials engineering and drug delivery system design principles.

Obvious Combinations & Variations

Source Patent Element
Apertured metallic capsule with nanophase tubular structure for fluid exchange
PTD Variation
Introducing a bicontinuous morphology and controlled 50-100 micron thickness for enhanced agent release
Obviousness Reasoning
Modifying nanoporous structure parameters is a predictable design optimization technique known to impact drug delivery performance, representing a routine engineering design choice
Source Patent Element
Nanotubes made of medical grade metals like titanium and stainless steel
PTD Variation
Adjusting nanotube diameter to 50-500 nm range to improve diffusion exchange
Obviousness Reasoning
Selecting specific nanotube dimensions is a well-established method for controlling material properties and agent release characteristics, representing a known technique in nanomaterials engineering
Source Patent Element
Substrate integrated with metallic capsule for facilitating fluid exchange
PTD Variation
Adding a rigid, through-porous membrane to enhance metabolically active agent release
Obviousness Reasoning
Incorporating additional membrane structures to improve drug delivery performance is a standard approach in biomedical device design, representing a finite set of predictable solution strategies
Source Patent Element
Nanophase tubular structure with 8-200 micron thickness
PTD Variation
Narrowing thickness range to 50-100 microns with specific bicontinuous morphology
Obviousness Reasoning
Refining material parameters through incremental adjustments is a standard engineering practice for optimizing device performance, representing a predictable variation within known design parameters
Source Patent Element
Nanotubes configured for fluid and diffusion exchange
PTD Variation
Implementing controlled nanoscale pore size to enhance agent release mechanisms
Obviousness Reasoning
Precise control of nanoscale structural features is a well-understood technique for modulating material properties, representing a routine optimization strategy in nanotechnology
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857673, a Person Having Ordinary Skill In The Art would find the variations disclosed in the Published Technical Disclosure to be obvious extensions of the prior art. The incremental modifications to nanoporous implantable device design represent predictable engineering solutions within the established technological framework, thereby rendering potential patent claims covering similar technical variations as anticipated and non-patentable under 35 U.S.C. Section 103.

Original Patent Information

Patent NumberUS 11,857,673
TitleImplantable cellular and biotherapeutic agent delivery canister
Assignee(s)NanoVault Medical LLC